Synthetic Biology in the Design and Development of Virus-Like Particle Vaccines
DOI:
https://doi.org/10.54097/56fyws94Keywords:
Virus-like particle, COVID-19, biosynthesis.Abstract
With the frequent emergence of new infectious diseases and the growing demand for precision medicine, the limitations of traditional vaccines are becoming increasingly apparent. Virus-like particles (VLPs) have become a key platform for the development of next-generation vaccines due to their combination of structural characteristics typical of natural viruses and a favorable safety profile. From the perspective of synthetic biology, this article reviews the working principles, production processes, and key construction technologies of VLP vaccines, with a focus on research progress regarding chassis protein design, engineering modification of antigen modules, optimization of linkage systems, and enhancement of structural stability. Meanwhile, the development status of marketed VLP vaccines, such as those for hepatitis B virus (HBV), hepatitis E virus (HEV), and human papillomavirus (HPV) is summarized, and the application of VLP vaccines currently in clinical research, including those for influenza, COVID-19, and HIV is analyzed. The results demonstrate that synthetic biology has significantly enhanced the programmability, immunogenicity, and development efficiency of VLP vaccines, driving their evolution toward multivalent, intelligent, and personalized forms. However, issues such as complex antigen display, large-scale production, and the evaluation of long-term protective efficacy remain to be addressed. Future research could further integrate AI-driven protein design, novel expression systems, and precision delivery technologies to advance the clinical translation and industrial application of VLP vaccines.
Downloads
References
[1] Shen Z L. Synthetic biology and virus vaccine development. Synthetic Biology Journal, 2023, 4(2): 333. DOI: 10.12211/2096-8280.2022-064.
[2] Shanghai Jiao Tong University. 125 Questions: Exploration and Discovery. Science, 2021. https://www.science.org/content/resource/125-questions-exploration-and-discovery
[3] Poria R, et al. Vaccine development: current trends and technologies. Life Sciences, 2024, 336: 122331. DOI: 10.1016/j.lfs.2023.122331. DOI: https://doi.org/10.1016/j.lfs.2023.122331
[4] Tan K, Zhang L L. Research progress on virus-like particle vaccines. Hubei Agricultural Sciences, 2021, 60(22): 5-10,18.
[5] Nooraei S, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. Journal of Nanobiotechnology, 2021, 19(1): 59. DOI: 10.1186/s12951-021-00806-7. DOI: https://doi.org/10.1186/s12951-021-00806-7
[6] Precision medicine meets cancer vaccines. Nature Medicine, 2023, 29(6): 1287. DOI: 10.1038/s41591-023-02432-2. DOI: https://doi.org/10.1038/s41591-023-02432-2
[7] Mohsen M O, Bachmann M F. Virus-like particle vaccinology, from bench to bedside. Cellular & Molecular Immunology, 2022, 19(9): 993-1011. DOI: 10.1038/s41423-022-00897-8. DOI: https://doi.org/10.1038/s41423-022-00897-8
[8] Li T, et al. Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections. Nature Biomedical Engineering, 2025. DOI: 10.1038/s41551-025-01529-y. DOI: https://doi.org/10.1038/s41551-025-01529-y
[9] Kou S, Sun C, Chen W, et al. Synthesis of chirally chimeric protein nanoparticle vaccines via mirror-image Spy chemistry. Angewandte Chemie International Edition, 2025, 64(34): e202509419. DOI: 10.1002/anie.202509419. DOI: https://doi.org/10.1002/anie.202509419
[10] Belghith A A, et al. Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates. Nature Communications, 2025, 16(1): 4726. DOI: 10.1038/s41467-025-59826-8. DOI: https://doi.org/10.1038/s41467-025-59826-8
[11] Pattyn J, Hendrickx G, Vorsters A, et al. Hepatitis B vaccines. The Journal of Infectious Diseases, 2021, 224(Suppl. 4): S343-S351. DOI: 10.1093/infdis/jiaa668. DOI: https://doi.org/10.1093/infdis/jiaa668
[12] Cocchio S, et al. Persistence of anti-HBs after up to 30 years in health care workers vaccinated against hepatitis B virus. Vaccines, 2021, 9(4): 323. DOI: 10.3390/vaccines9040323. DOI: https://doi.org/10.3390/vaccines9040323
[13] Halperin S A, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine, 2012, 30(15): 2556-2563. DOI: 10.1016/j.vaccine.2012.01.087. DOI: https://doi.org/10.1016/j.vaccine.2012.01.087
[14] Bachmann M F, Van Damme P, Lienert F, et al. Virus-like particles: a versatile and effective vaccine platform. Expert Review of Vaccines, 2025, 24(1): 444-456. DOI: 10.1080/14760584.2025.2508517. DOI: https://doi.org/10.1080/14760584.2025.2508517
[15] Yadav K K, Kenney S P. Hepatitis E virus immunosuppressed animal models. BMC Infectious Diseases, 2024, 24(1): 965. DOI: 10.1186/s12879-024-09870-4. DOI: https://doi.org/10.1186/s12879-024-09870-4
[16] Zhu F C, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. The Lancet, 2010, 376(9744): 895-902. DOI: 10.1016/S0140-6736(10)61030-6. DOI: https://doi.org/10.1016/S0140-6736(10)61030-6
[17] Molina M A, Steenbergen R D M, Pumpe A, et al. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends in Molecular Medicine, 2024, 30(9): 890-902. DOI: 10.1016/j.molmed.2024.05.009. DOI: https://doi.org/10.1016/j.molmed.2024.05.009
[18] Paavonen J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet, 2007, 369: 2161-2170. DOI: 10.1016/S0140-6736(07)60946-5. DOI: https://doi.org/10.1016/S0140-6736(07)60946-5
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

